Casandra
Casandra Test Code NG49325Version 1 (DRAFT)
Performing Lab
JAK2 V617F Mutation Analysis - Quantitative
Also known as: JAK2 V617F Quantitative Analysis
Clinical Use
Order TestUse
The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately half of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Quantitation of V617F is useful for monitoring myeloproliferative neoplasm (MPN) patients’ response to clinical treatment because mutational load correlates with disease course, making it a useful predictive marker.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
New York Approved
Methodology
PCR‑based (qPCR)
Biomarkers
JAK2
GeneSNVs + Indels
Mutation • Categorical (e.g., Positive / Negative / Indeterminate)
Result Turnaround Time
7 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube